Skip to main content
. 2021 Mar 31;5(7):1837–1847. doi: 10.1182/bloodadvances.2020003453

Table 2.

Baseline characteristics of patients in the LDC and SDC cohorts

Characteristic LDC* SDC Total P
Sex 83 100 183 .355
 Male 45 (54.2) 61 (61.0) 106 (57.9)
 Female 38 (45.8) 39 (39.0) 77 (42.1)
Age, y 83 100 183 .424
 Median 6.1 7.5 6.8
 Range 0.8-14.2 0.3-13.8 0.3-14.2
WBC count, × 10 9 /L 83 100 183 .001
 Median 12.48 27.67 17.9
 Range 1.33-283.41 0.42-606 0.42-606
FAB subtype 83 100 183 .058
 M1/M2 38 (45.8) 43 (43.0) 81 (44.3)
 M4/M5 31 (37.4) 49 (49.0) 80 (43.7)
 M6 0 1 (1.0) 1 (0.5)
 M7 7 (8.4) 1 (1.0) 8 (4.4)
 Unclassified 7 (8.4) 6 (6.0) 13 (7.1)
Gene rearrangements 83 100 183 .432
 RUNX1–RUNX1T1 33 (39.8) 35 (35.0) 68 (37.1)
 KMT2Ar 11 (13.2) 14 (14.0) 25 (13.7)
 CBF/MYH11 6 (7.2) 15 (15.0) 21 (11.5)
 BCR–ABL 0 1 (1.0) 1 (0.5)
 Negative 33 (39.8) 35 (35.0) 68 (37.2)
Gene mutations 76 92 168 .168
 C-KIT 19 (25.0) 23 (25.0) 42 (25.0)
 CEBPα biallelic mutation 6(7.9) 3(3.3) 9(5.4)
 FLT3-ITD 4(5.3) 12(13.0) 16(9.5)
 WT1 4(5.3) 0 4(2.4)
 NPM1 2 (2.6) 1(1.1) 3 (1.8)
 PTPN11 2 (2.6) 2 (2.2) 4 (2.4)
 Other 6(7.9) 6(6.5) 12(7.1)
 Negative 33 (43.4) 45 (48.9) 78 (46.4)
Provisional risk group 83 100 183 .035
 Low 10 (12.0) 15 (15.0) 25 (13.7)
 Intermediate 56 (67.5) 49 (49.0) 105 (57.3)
 High 17 (20.5) 36 (36.0) 53 (29.0)
Definitive risk group 77 95 172 .016
 Low 10 (13.0) 15 (15.8) 25 (14.5)
 Intermediate 51 (66.2) 43 (45.3) 94 (54.7)
 High 16 (20.8) 37 (38.9) 53 (30.8)

Data are presented as n (%), unless otherwise specified.

NR, no remission.

*

Selected data on 46 study patients have been previously reported.20

The Mann-Whitney U test was used for continuous variables; Fisher’s exact test was used for categorical variables with 2×2 charts; Monte Carlo analysis was used for categorical variables with N×2 charts.